Sign Up Today and Learn More About SynOx Therapeutics Stock
Invest in or calculate the value of your shares in SynOx Therapeutics or other pre-IPO companies through EquityZen's platform.
SynOx Therapeutics Stock (SYTH)
SynOx Therapeutics is a biotechnology research company that focused on developing the treatment of diffuse tenosynovial giant cell tumors.
About SynOx Therapeutics Stock
Founded
2020
Industries
Software, Artificial Intelligence, Data and Analytics
SynOx Therapeutics Press Mentions
Stay in the know about the latest news on SynOx Therapeutics
SynOx Therapeutics Receives Fast Track Designation from U.S. Food and Drug Administration for Emactuzumab for Tenosynovial Giant Cell Tumours (TGCT)
biospace • Apr 14, 2025
SynOx Therapeutics Announces Board Chair Transition to Align with Advancing Regulatory and Commercialization Strategy
biospace • Apr 02, 2025
SynOx Therapeutics Announces Board Chair Transition to Align with Advancing Regulatory and Commercialization Strategy
globenewswire • Apr 01, 2025
Synrx Therapeutics discovers new POLθ inhibitors
bioworld • Feb 06, 2025
From The Philippines To Argentina, These Four Countries Saw Startup Funding Rise
news • Jan 30, 2025
SynOx Therapeutics Management
Leadership team at SynOx Therapeutics
Board Member
Francesco Rubertis
Board Member
Jacob Gunterberg
Join now and verify your accreditation status to gain access to:
- SynOx Therapeutics Current Valuation
- SynOx Therapeutics Stock Price
- SynOx Therapeutics Management
- Available deals in SynOx Therapeutics and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- SynOx Therapeutics Cap Table and Funding History by Share Class and Liquidity Preferences
- SynOx Therapeutics Revenue and Financials
- SynOx Therapeutics Highlights
- SynOx Therapeutics Business Model
- SynOx Therapeutics Risk Factors
- SynOx Therapeutics Research Report from SACRA Research
Trading SynOx Therapeutics Stock
How to invest in SynOx Therapeutics stock?
Accredited investors can buy pre-IPO stock in companies like SynOx Therapeutics through EquityZen funds. These investments are made available by existing SynOx Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell SynOx Therapeutics stock?
Shareholders can sell their SynOx Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 370K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 46K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
